A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

NCT05848739 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Colon Cancer
Metastatic Colon Cancer

Interventions

DRUG: ST316
DRUG: FOLFIRI regimen & bevacizumab
DRUG: Fruquintinib
DRUG: Lonsurf & bevacizumab

Sponsor

Sapience Therapeutics